Important Safety Information

  • The most common adverse reactions in clinical studies (≥ 3% of Aimovig-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig full Prescribing Information.


Indication

Aimovig is indicated for the preventive treatment of migraine in adults.
Aimovig Ally™ logo

Committed to helping your patients start and stay on Aimovig as prescribed

Resources for you and your patients

Click here for downloadable
resources

Our Service Request Form (SRF) is the only form you’ll need to complete to get appropriate patients started on Aimovig™ and the Aimovig Ally™ suite of product support services.

Submit a Service Request Form (SRF) today
Aimovig Ally is dedicated to supporting your patients taking Aimovig. We’ll help make the process seamless with personalized product services and support.
  • A seamless start

    We’ve made it simple for your patients to start Aimovig. Our Service Request Form is all you need to help your patients access the services Aimovig Ally has to offer.

     
  • Ongoing product support

    We’re here to help ensure your patients and your staff have ongoing product support with Aimovig. Our support teams offer injection demonstrations, support in-office or over the phone, ongoing education, and more.

     
  • Access and financial resources for your patients

    Eligible patients with commercial insurance can get help with out-of-pocket costs through our Copay Program. Eligibility criteria and program limits apply. We can also help identify other access resources.

     
Download and provide patients with our copay program brochure so they can enroll today

Note: Completing the SRF form also helps allow eligible patients to sign up for the Copay Program.


Ready to get started?

Simply call our Aimovig Ally support team at 833-AIMOVIG
(833-246-6844), Monday–Friday, 8 am–8 pm ET


Aimovig
free trial offer*
With the Aimovig™ Free Trial Offer,* patients can try 2 months of product at no
cost to see if it is right for them. Eligibility criteria and program limits apply.
 

*Free trial is optional and available at no cost to patients new to Aimovig™. Patients are eligible to receive two doses of Aimovig™ dispensed directly from the Aimovig Ally™ support program pharmacy. Doses are delivered on a monthly basis and will be coordinated with the patient. If the dose changes, please contact the Program. No purchase required. Patient may only redeem this offer once. This free trial is not health insurance and is not contingent on or a guarantee of insurance coverage. Limitations may apply. Not available to residents of Massachusetts. Novartis Pharmaceuticals Corporation and Amgen reserve the right to rescind, revoke, or amend this offer without notice. Enrollment must occur by 12/31/2018.

Program details:
With the Aimovig™ Copay Program, eligible patients may pay as little as $5 out-of-pocket up to a $2700 annual maximum. This applies to deductible, co-insurance, and copayments for Aimovig™. The offer is valid for unlimited uses provided the patient re-enrolls. A valid Prescriber ID # is required on the prescription. The program provides out-of-pocket assistance for a patient in a 1-year period dating from initial activation. Patient is responsible for costs above annual maximum. Patient may use the card each time the patient fills the Aimovig™ prescription. In order to remain eligible, the patient must renew participation in the program every 12 months by visiting www.aimovig.com/copay or calling 833-AIMOVIG (833-246-6844).

Eligibility criteria:
Patient must be prescribed Aimovig™. The Aimovig™ Copay Program is available to patients with commercial insurance and 18 years or older. The program is not open to patients receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DOD), or TRICARE or where prohibited by law. If at any time patients begin receiving coverage under any such federal-, state-, or government-funded healthcare program, patients will no longer be able to use this card and patient must call 833-AIMOVIG to stop participation. Patients may not seek reimbursement for value received from Aimovig™ Copay Program from any third-party payers, including flexible spending accounts or healthcare savings accounts. The program is only valid in the United States, Puerto Rico, and the US territories. Other restrictions may apply. The offer is subject to change or discontinuation without notice. This is not health insurance.

Indication

Aimovig is indicated for the preventive treatment of migraine in adults.

Important Safety Information

Please see Aimovig full Prescribing Information.